Switching from a ritonavir-boosted protease inhibitor to a dolutegravir-based regimen for maintenance of HIV viral suppression in patients with high cardiovascular risk

OBJECTIVE: To compare the efficacy, safety, and impact on lipid fractions of switching from a ritonavir-boosted protease inhibitor (PI/r) to a dolutegravir (DTG) regimen. METHODS: HIV type 1-infected adults more than 50 years or with a Framingham score more than 10% were eligible if plasma HIV RNA l...

Descripción completa

Detalles Bibliográficos
Autores principales: Gatell, José M., Assoumou, Lambert, Moyle, Graeme, Waters, Laura, Johnson, Margaret, Domingo, Pere, Fox, Julie, Martinez, Esteban, Stellbrink, Hans–Jürgen, Guaraldi, Giovanni, Masia, Mar, Gompels, Mark, De Wit, Stephane, Florence, Eric, Esser, Stefan, Raffi, François, Pozniak, Anton L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2017
Materias:
Clinical Science
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5690310/
https://www.ncbi.nlm.nih.gov/pubmed/29112070
http://dx.doi.org/10.1097/QAD.0000000000001675

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5690310/
https://www.ncbi.nlm.nih.gov/pubmed/29112070
http://dx.doi.org/10.1097/QAD.0000000000001675

Ejemplares similares